IONS|Ionis Pharmaceuticals Inc|株価:72.700|

詳細情報 Ionis Pharmaceuticals Inc 企業名

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Ionis Pharmaceuticals Incの企業情報



企業コードIONS

会社名Ionis Pharmaceuticals Inc

上場日May 17, 1991

最高経営責任者「CEO」Monia (Brett P)

従業員数1069

証券種類Ordinary Share

決算期末May 17

本社所在地2855 Gazelle Court

都市CARLSBAD

証券取引所NASDAQ OMX - NASDAQ BASIC

国United States of America

郵便番号92010

電話番号17609319200

ウェブサイトhttps://www.ionis.com/

企業コードIONS

上場日May 17, 1991

最高経営責任者「CEO」Monia (Brett P)

Ionis Pharmaceuticals Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

242.66K

-5.08%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.61%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

82.66K

-60.76%

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

66.60K

+0.53%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

65.67K

+27.71%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

62.21K

-16.31%

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

59.66K

--

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Chairman of the Board

36.33K

--

Dr. Eric E. Swayze, Ph.D.

Executive Vice President - Research

32.48K

-47.37%

Ms. Shannon L. Devers

Chief Human Resources Officer, Executive Vice President

22.54K

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

242.66K

-5.08%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.61%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

82.66K

-60.76%

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

66.60K

+0.53%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

65.67K

+27.71%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

62.21K

-16.31%

収益内訳

通貨: USD更新時刻: Mar 4, 2025

FY2020

FY2019

事業別USD

会社名

収益

比率

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

会社から関連データがまだ開示されていません。

事業別

地域別

事業別USD

会社名

収益

比率

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

株主

更新時刻: Fri, Feb 20

株主統計

種類

株主統計

比率

Fidelity Management & Research Company LLC

14.57%

Capital World Investors

10.87%

The Vanguard Group, Inc.

9.93%

T. Rowe Price Investment Management, Inc.

5.51%

BlackRock Institutional Trust Company, N.A.

5.23%

他の

53.88%

株主統計

比率

Fidelity Management & Research Company LLC

14.57%

Capital World Investors

10.87%

The Vanguard Group, Inc.

9.93%

T. Rowe Price Investment Management, Inc.

5.51%

BlackRock Institutional Trust Company, N.A.

5.23%

他の

53.88%

種類

株主統計

比率

Investment Advisor

69.38%

Investment Advisor/Hedge Fund

20.02%

Hedge Fund

12.12%

Research Firm

1.94%

Pension Fund

1.01%

Bank and Trust

0.89%

Individual Investor

0.82%

Sovereign Wealth Fund

0.19%

Insurance Company

0.16%

機関投資家保有株



更新時刻: Thu, Jan 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q4

884

176.89M

109.21%

-8.44M

2025Q3

815

172.95M

106.78%

-7.24M

2025Q2

801

185.40M

116.34%

+8.33M

2025Q1

826

174.18M

109.45%

-1.97M

2024Q4

819

166.51M

104.84%

-2.69M

2024Q3

814

162.85M

103.55%

+6.60M

2024Q2

810

149.96M

102.64%

-3.87M

2024Q1

792

148.14M

101.63%

-5.27M

2023Q4

782

147.15M

102.53%

-3.26M

2023Q3

763

145.13M

101.24%

-1.40M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

Fidelity Management & Research Company LLC

23.69M

14.63%

+46.05K

+0.19%

Sep 30, 2025

Capital World Investors

17.96M

11.09%

+5.24M

+41.17%

Dec 31, 2025

The Vanguard Group, Inc.

16.44M

10.15%

-235.68K

-1.41%

Sep 30, 2025

T. Rowe Price Investment Management, Inc.

13.16M

8.12%

-2.89M

-18.02%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

8.45M

5.22%

-272.23K

-3.12%

Sep 30, 2025

Wellington Management Company, LLP

6.59M

4.07%

+243.03K

+3.83%

Sep 30, 2025

Two Sigma Investments, LP

3.65M

2.25%

-806.92K

-18.11%

Sep 30, 2025

Bellevue Asset Management AG

6.24M

3.86%

-1.61M

-20.49%

Sep 30, 2025

State Street Investment Management (US)

4.39M

2.71%

-141.75K

-3.13%

Sep 30, 2025

Geode Capital Management, L.L.C.

3.07M

1.89%

+175.19K

+6.06%

Sep 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

配当落ち日

種類

比率

データなし

日付

配当落ち日

種類

比率

データなし

Ionis Pharmaceuticals Inc

詳細情報 Ionis Pharmaceuticals Inc 企業名

Ionis Pharmaceuticals Incの企業情報

Ionis Pharmaceuticals Incの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割